文献速递鼻科

两种商业屋尘螨提取物治疗过敏性鼻炎的疗效与安全性头对头研究

The efficacy and safety of two commercial house dust mite extracts for allergic rhinitis: a head-to-head study.
PubMed 文献 · Int Forum Allergy Rhinol · 2019-07-19

该开放标签随机研究纳入230例中国屋尘螨相关过敏性鼻炎患者,比较Dp提取物(Alutard SQ)与Dp/Df提取物(NovoHelisen Depot)皮下注射1年的疗效与安全性。两组CSMS较基线均显著下降(1.8 vs 3.1和1.8 vs 3.3,均p<0.001),组间疗效与全身反应率无差异,未发生过敏反应。

要点

  • 两种屋尘螨提取物皮下免疫治疗1年均显著降低CSMS,组间疗效相当。
  • 全身反应率Alutard组14.8%、NHD组11.3%,组间无差异且无过敏反应。
  • 两组治疗后Dp和Df特异性IgG4及IgE阻断因子均显著升高。

核心结论

  • 两种商业屋尘螨提取物在中国屋尘螨相关过敏性鼻炎患者中疗效与安全性相当。

研究设计与样本

  • 开放标签随机研究,230例屋尘螨相关过敏性鼻炎患者随机分入Alutard SQ组和NovoHelisen Depot组,皮下注射1年并每3个月随访。

主要发现

  • Alutard组CSMS从3.1降至1.8(p<0.001),NHD组从3.3降至1.8(p<0.001)。
  • 两组在CSMS、症状评分和药物评分方面疗效相当(p>0.05)。
  • Alutard组17例(14.8%)和NHD组13例(11.3%)发生全身反应,组间无差异(p>0.05),无过敏反应发生。
  • 治疗1年后两组Dp和Df特异性IgG4及IgE阻断因子均显著升高。

关键数值与推荐

  • 主要终点为疗效评估期总 combined 症状与药物评分(CSMS)。
  • 全身反应率组间比较p>0.05,无过敏反应。

临床怎么用

  • 两种屋尘螨提取物均可用于中国屋尘螨相关过敏性鼻炎患者的皮下免疫治疗,疗效与安全性相当。

局限性

  • 本研究为开放标签设计,29例患者脱落。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several studies have demonstrated the efficacy of house dust mite (HDM) immunotherapy in allergic rhinitis (AR). We aimed to compare the efficacy and safety of 2 commercial HDM extracts in a Chinese AR population. METHODS: This was an open-label study. HDM-associated AR patients were randomized into Dermatophagoides pteronyssinus (Dp) extracts (Alutard SQ; ALK, Hørsholm, Denmark) and Dp/Dermatophagoides farinae (Df) extracts (NovoHelisen Depot [NHD]; Allergopharma, Reinbek, Germany) groups. All patients received subcutaneous injections for 1 year, and were followed every 3 months during that 1-year period. Symptom score, medication score, and adverse reactions were recorded. The primary endpoint was the total combined symptom and medication score (CSMS) during the efficacy evaluation period. Blood samples were taken for specific immunoglobulin E (IgE), IgG4, and IgE-blocking factor tests at baseline and after the 1-year treatment. RESULTS: A total of 230 AR patients were randomized; 29 patients dropped out. Analysis of the primary endpoint demonstrated significant reductions in CSMS of 1.8 vs 3.1 (p < 0.001) in the Alutard group and 1.8 vs 3.3 (p < 0.001) in the NHD group compared with baseline. The 2 groups presented equal effectiveness with regard to CSMS, symptom score, and medication score (p > 0.05). The treatment was well tolerated in both groups; 17 (14.8%) patients experienced systemic reactions (SRs) in the Alutard group and 13 (11.3%) in the NHD group. The rates of SRs showed no difference in the 2 groups (p > 0.05), and no anaphylaxis occurred. IgG4 and IgE-blocking factor to Dp and Df were increased significantly in both groups after the 1-year treatment. CONCLUSION: Our study confirmed the equal efficacy and safety profile of both commercial extracts in HDM-associated AR patients.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Li J, Wu Y, Yang Y, et al. The efficacy and safety of two commercial house dust mite extracts for allergic rhinitis: a head-to-head study. Int Forum Allergy Rhinol. 2019. PMID: 31322838. doi:10.1002/alr.22343

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。